**Supplementary Table 4.** PAH-targeted therapies.

|  |  |
| --- | --- |
| Mono | 8 |
| Dual | 72 (45%) |
| Triple | 78 (49%) |

Treatment regimens for all patients in the cohort included PAH-targeted therapies, such as phosphodiesterase-5 inhibitors, endothelin receptor antagonists, prostacyclins, and soluble guanylate cyclase stimulators. Additionally, one patient received calcium channel blockers along with PAH-targeted therapies. Combination therapy was based on disease severity and guideline recommendations.